JP2004537500A - 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 - Google Patents

腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 Download PDF

Info

Publication number
JP2004537500A
JP2004537500A JP2002555834A JP2002555834A JP2004537500A JP 2004537500 A JP2004537500 A JP 2004537500A JP 2002555834 A JP2002555834 A JP 2002555834A JP 2002555834 A JP2002555834 A JP 2002555834A JP 2004537500 A JP2004537500 A JP 2004537500A
Authority
JP
Japan
Prior art keywords
inhibitor
subject
virus
tumor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002555834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537500A5 (enExample
Inventor
ジェイ エイ． バーゾフスキー，
マサキ テラベ，
デブラ ディー． ドナルドソン，
ソウ マツイ，
ナンシー ノベン−トゥルース，
ウイリアム イー． ポール，
Original Assignee
ジェネティクス インスティテュート，エルエルシー
ザ ガバメント オブ ザ ユナイテッド ステイツ アズ レプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26981351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004537500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネティクス インスティテュート，エルエルシー, ザ ガバメント オブ ザ ユナイテッド ステイツ アズ レプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ filed Critical ジェネティクス インスティテュート，エルエルシー
Publication of JP2004537500A publication Critical patent/JP2004537500A/ja
Publication of JP2004537500A5 publication Critical patent/JP2004537500A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2002555834A 2000-10-20 2001-10-22 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 Pending JP2004537500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69360000A 2000-10-20 2000-10-20
US31818501P 2001-09-07 2001-09-07
PCT/US2001/051339 WO2002055100A2 (en) 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008262301A Division JP2009046512A (ja) 2000-10-20 2008-10-08 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2004537500A true JP2004537500A (ja) 2004-12-16
JP2004537500A5 JP2004537500A5 (enExample) 2005-04-21

Family

ID=26981351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002555834A Pending JP2004537500A (ja) 2000-10-20 2001-10-22 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
JP2008262301A Pending JP2009046512A (ja) 2000-10-20 2008-10-08 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008262301A Pending JP2009046512A (ja) 2000-10-20 2008-10-08 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物

Country Status (8)

Country Link
EP (2) EP1333850B1 (enExample)
JP (2) JP2004537500A (enExample)
AT (1) ATE405282T1 (enExample)
AU (1) AU2002243443A1 (enExample)
DE (1) DE60135481D1 (enExample)
DK (1) DK1333850T3 (enExample)
ES (1) ES2311558T3 (enExample)
WO (1) WO2002055100A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
JP2017014254A (ja) * 2014-02-21 2017-01-19 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
CA2557724A1 (en) * 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
AU2010269120B2 (en) * 2009-07-06 2015-09-24 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
AU2024297239A1 (en) * 2023-07-12 2026-02-05 Leidos Biomedical Research Inc. Compositions and methods for the inhibition of natural killer cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0656947A1 (en) * 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JPH09150569A (ja) 1995-11-29 1997-06-10 Riso Kagaku Corp 色画像形成用シート
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US7507706B1 (en) * 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
DE60017115T2 (de) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6008016323, ＲＵＴＨ， Ｊ．Ｈ．， ｅｔ ａｌ．, "ＩＮＴＥＲＬＥＵＫＩＮ ４ ＡＮＤ １３ ＰＡＲＴＩＣＩＰＡＴＩＯＮ ＩＮ ＭＹＣＯＢＡＣＴＥＲＩＡＬ （ｔｙｐｅ−１） ＡＮＤ ＳＣＨＩＳＴＯＳＯＭＡＬ （ｔｙｐｅ−２） ＡＮＴＩＧＥＮ−ＥＬＩＣＩ", ＣＹＴＯＫＩＮＥ, 200005, Ｖｏｌ．１２， Ｎｏ．５, ｐ．４３２−４４４ *
JPN6008016324, ＳＥＲＶＥ， Ｈ．， ｅｔ ａｌ．, "Ｉｎｈｉｂｉｔｉｏｎ ｏｆ Ｐｒｏｌｉｆｅｒａｔｉｏｎ ａｎｄ Ｃｌｏｎａｌ Ｇｒｏｗｔｈ ｏｆ Ｈｕｍａｎ Ｂｒｅｓｔ Ｃａｎｃｅｒ Ｃｅｌｌｓ ｂｙ Ｉｎｔｅｒｌｅｕｋｉｎ １３", ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, 19960801, Ｖｏｌ．５６， Ｎｏ．１５, ｐ．３５８３−３５８８ *
JPN6008016325, ＢＡＩＬＥＲ， Ｒ．Ｔ．， ｅｔ ａｌ．, "ＩＬ−１３ ａｎｄ ＴＮＦ−α ｉｎｈｉｂｉｔ ｄｕａｌ−ｔｒｏｐｉｃ ＨＩＶ−１ ｉｎ ｐｒｉｍａｒｙ ｍａｃｒｏｐｈａｇｅｓ ｂｙ ｒｅｄｕｃｔｉｏｎ ｏｆ ｓｕｒｆａｃｅ ｅｘｐｒｅｓｓｉｏｎ", ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＩＭＭＵＮＯＬＯＧＹ, 200005, Ｖｏｌ．３０， Ｎｏ．５, ｐ．１３４０−１３４９ *
JPN6008016326, ＣＨＩＡＲＡＭＯＮＴＥ， Ｍ．Ｇ．， ｅｔ ａｌ．, "Ａｎ ＩＬ−１３ ｉｎｈｉｂｉｔｏｒ ｂｌｏｃｋｓ ｔｈｅ ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ｈｅｐａｔｉｃ ｆｉｂｒｏｓｉｓ ｄｕｒｉｎｇ ａ Ｔ−ｈｅｌｐｅｒ ｔｙｐｅ ２−ｄｏｍｉｎａｔｅｄ ｉｎｆ", Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｉｎｖｅｓｔｉｇａｔｉｏｎ, 199909, Ｖｏｌ．４０１， Ｎｏ．６, ｐ．７７７−７８５ *
JPN6008016327, ＬＯＰＥＺ， Ｍ．， ｅｔ ａｌ．, "ＩＬ−１３ ｉｎｄｕｃｅｓ ＣＤ３４＋ ｃｅｌｌｓ ｉｓｏｌａｔｅｄ ｆｒｏｍ Ｇ−ＣＳＦ ｍｏｂｉｌｉｚｅｄ ｂｌｏｏｄ ｔｏ ｄｉｆｆｅｒｅｎｔｉａｔｅ ｉｎ ｖｉｔｒｏ ｉｎｔｏ ｐｏｔｅｎｔ", Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｉｃａｌ Ｍｅｔｈｏｄｓ, 19971027, Ｖｏｌ．２０８， Ｎｏ．２, ｐ．１１７−１２９ *
JPN7008003165, ＬＥＢＥＬ−ＢＩＮＡＹ， Ｓ．， ｅｔ ａｌ．, "Ｅｘｐｅｒｉｍｅｎｔａｌ ｇｅｎｅ ｔｈｅｒａｐｙ ｏｆ ｃａｎｃｅｒ ｕｓｉｎｇ ｔｕｍｏｒ ｃｅｌｌｓ ｅｎｇｅｎｅｅｒｅｄ ｔｏ ｓｅｃｒｅｔｅ ｉｎｔｅｒｌｅｕｋｉｎ−１３", ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＩＭＭＵＮＯＬＯＧＹ, 199508, Ｖｏｌ．２５， Ｎｏ．８, ｐ．２３４０−２３４８ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
JP2017014254A (ja) * 2014-02-21 2017-01-19 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
JPWO2015125652A1 (ja) * 2014-02-21 2017-03-30 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
JP2019070056A (ja) * 2014-02-21 2019-05-09 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
JP7041439B2 (ja) 2014-02-21 2022-03-24 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤

Also Published As

Publication number Publication date
WO2002055100A9 (en) 2006-05-11
ATE405282T1 (de) 2008-09-15
EP1333850B1 (en) 2008-08-20
DE60135481D1 (de) 2008-10-02
EP1333850A2 (en) 2003-08-13
WO2002055100A3 (en) 2003-03-27
JP2009046512A (ja) 2009-03-05
AU2002243443A8 (en) 2005-10-13
EP2027867A1 (en) 2009-02-25
DK1333850T3 (da) 2008-12-01
AU2002243443A1 (en) 2002-07-24
WO2002055100A2 (en) 2002-07-18
ES2311558T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
JP2009046512A (ja) 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
US7504101B2 (en) Methods for enhancing antigen-specific immune response using antibodies that bind OX-40
EP1060247B1 (en) Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
Alexander-Miller et al. Supraoptimal peptide–major histocompatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor α receptor II–mediated apoptosis of cytotoxic T lymphocytes
JP4787439B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
Saha et al. Combination of CTL‐associated Antigen‐4 blockade and depletion of CD25+ regulatory T cells enhance tumour immunity of dendritic cell‐based vaccine in a mouse model of colon cancer
Pippig et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40)
US20230078665A1 (en) Cell compositions and methods for cancer therapy
US20030039653A1 (en) Methods of enhancing T cell responsiveness
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
Takayama et al. Antigen-specific directional target cell lysis by perforin-negative T lymphocyte clones
USRE39789E1 (en) Tumor therapy
AU2002302070B2 (en) Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
MXPA00008176A (en) Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
HK1126246A (en) Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
Sutherland BAFF regulation of peripheral T cell responses
NZ788539A (en) Anti-gitr antibodies and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100531